West Point Pharmaceutical: Third Quarter Report of 2025
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
Securities code: 301130 Securities abbreviation: West Point Pharmaceutical Announcement number: 2025-071
Jilin Xidian Pharmaceutical Technology Development Co., Ltd.
2025 Third Quarter Report
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions. Important content reminder:
The board of directors, directors and senior managers guarantee that the quarterly report is true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
Whether the third quarter financial accounting report has been audited
□Yes No
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
1. Main financial data
(1) Main accounting data and financial indicators
Whether the company needs to retroactively adjust or restate previous years’ accounting data
□Yes No
This reporting period compared with the same period last year. From the beginning to the end of the reporting period. Compared with the same period last year. From the beginning to the end of the reporting period.
Increase/decrease Increase/decrease in operating income during the same period of the year (yuan) 60,633,576.33 -4.68% 188,945,385.60 -1.89% attributed to shareholders of listed companies
8,201,777.34 -14.70% 33,146,362.42 -2.70% net profit (yuan)
Attributable to shareholders of listed companies
Net profit after deducting non-recurring gains and losses 6,422,574.06 -20.26% 29,808,580.48 3.19% (yuan)
Cash generated from operating activities
-- -- 38,510,024.22 -16.43% Net flow (yuan)
Basic earnings per share (yuan/
0.1072 -14.38% 0.4333 -0.41% shares)
Diluted earnings per share (yuan/
0.1072 -14.38% 0.4333 -0.41% shares)
weighted average net asset income
0.90% -0.17% 3.63% -0.01% rate
End of the reporting period End of the previous year Increase or decrease in total assets at the end of the reporting period compared with the end of the previous year (yuan) 1,053,157,800.60 1,062,575,503.79 -0.89% attributable to shareholders of the listed company
916,731,759.27 905,746,474.33 1.21% owner’s equity (yuan)
(2) Non-recurring profit and loss items and amounts
Applicable □Not applicable
Unit: Yuan
Item Amount for this reporting period Amount from the beginning of the reporting period to the end of the reporting period Explanation of gains and losses from disposal of non-current assets (including
Including the offset of the provision for asset impairment -149.57 -289.57 and the write-off of fixed asset scrapping losses)
Except related to the company's normal business operations
In addition to effective hedging business, non-
Financial enterprises hold financial assets and funds raised and own funds for cash
1,462,483.49 3,103,935.90
Changes in fair value of financial liabilities, gains and losses from financial management, and disposal of financial assets and financial
Profit and loss arising from financial liabilities
Other businesses other than the above
67,892.14 62,283.55
external income and expenses
Others comply with the definition of non-recurring gains and losses, advanced manufacturing super deduction, personal income tax
809,680.28 1,025,120.13
Profit and loss items, handling fees, etc.
Less: Income tax impact 350,985.95 628,657.50
Amount affected by minority shareholders’ equity
209,717.11 224,610.57
(after tax)
Total 1,779,203.28 3,337,781.94 --
Details of other profit and loss items that meet the definition of non-recurring profits and losses:
Applicable □Not applicable
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
Advanced manufacturing super deduction, individual tax handling fees, etc.
Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items
Applicable □Not applicable
Item Amount involved (yuan) Reason
Government subsidies with an amortization period of 5 years or more are the same as
Government subsidies closely related to the company's normal operating business and with a loss amortization period of 5 years or more 2,504,493.81
have a lasting impact. Therefore, the company will
Classified as recurring profit and loss items.
(3) Changes in major accounting data and financial indicators and their reasons
□Applicable Not applicable
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders
Unit: Share Total number of common shareholders at the end of the reporting period 7,863 Total number of preference shareholders with restored voting rights at the end of the reporting period (if any) 0 Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Holding of sales restrictions Pledge, mark or freeze Name of shareholder Nature of shareholder Shareholding ratio Number of shares held
Number of shares in the case Share status Quantity Zhang Jun Domestic natural person 25.66% 19,627,034 14,720,275 Not applicable 0 Dingdian Investment Management
(Beijing) Co., Ltd.
Company - Hengqin Ding
Others 7.86% 6,013,154 0 Not applicable 0 Equity investment fund
gold partnership
(limited partnership)
Zhuhai Hengqin Yanhe
Domestic non-state-owned laws
Health Technology Co., Ltd. 4.83% 3,697,400 0 Not applicable 0
people
company
Dingdian Investment Management
(Beijing) Co., Ltd.
Company - Hengqin Run
Others 4.06% 3,106,717 0 Not applicable 0 Huiyi Equity Investment
fund partnership
(limited partnership)
SDIC Hi-Tech Investment
State-owned legal person 3.25% 2,483,997 0 Not applicable 0 Limited company
Quartzxiu Domestic natural person 2.03% 1,554,017 1,494,088 Not applicable 0 Shi Shilin Domestic natural person 2.00% 1,530,000 0 Not applicable 0 Shanghai Ah Xing Investment
Management Co., Ltd.
- Ah Xing Xingren 2 Others 1.83% 1,400,400 0 Not applicable No. 0 Private Securities Investment
capital fund
Meng Yonghong Domestic natural person 1.80% 1,376,249 1,032,187 Not applicable 0 Zhejiang Yinwan Private Equity
Fund Management Limited
Company - Yinwanquan Others 1.78% 1,362,300 0 Not applicable 0 Ying 66 Private Equity
securities investment funds
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
Shareholdings of the top 10 shareholders without sales restrictions (excluding shares lent through refinancing and shares locked by executives)
Type and quantity of shares
Name of shareholder Number of shares without selling restrictions held
Share Type Quantity
Dingdian Investment Management (Beijing) Co., Ltd.
- Hengqin Dingdian Equity Investment Fund Partnership 6,013,154 RMB ordinary shares 6,013,154 (limited partnership)
Zhang Jun 4,906,759 RMB ordinary shares 4,906,759
Zhuhai Hengqin Yanhe Health Technology Co., Ltd. 3,697,400 RMB ordinary shares 3,697,400
Dingdian Investment Management (Beijing) Co., Ltd.
- Hengqin Runhuiyi Equity Investment Fund Partnership 3,106,717 RMB ordinary shares 3,106,717 Enterprise (limited partnership)
SDIC High-tech Investment Co., Ltd. 2,483,997 RMB ordinary shares 2,483,997
Shi Shilin 1,530,000 RMB ordinary shares 1,530,000
Shanghai Ah Xing Investment Management Co., Ltd.-A
1,400,400 RMB ordinary shares 1,400,400 Xingxing No. 2 Private Securities Investment Fund
Zhejiang Yinwan Private Equity Fund Management Co., Ltd.
- Yinwan Quanying No. 66 Private Securities Investment 1,362,300 RMB ordinary shares 1,362,300 Fund
Li Weiping 871,238 RMB ordinary shares 871,238
Zhejiang Yinwan Private Equity Fund Management Co., Ltd.
- Yinwanquanying No. 16 Private Securities Investment 757,400 RMB ordinary shares 757,400 Fund
The fund managers of Hengqin Dingdian Equity Investment Fund Partnership (Limited Partnership) and Hengqin Runhuiyi Equity Investment Fund Partnership (Limited Partnership) are both Dingdian Investment Management (Beijing) Co., Ltd. Hengqin Dingdian Equity Investment Fund Partnership (Limited Partnership) and Hengqin Runhuiyi Equity Investment Fund Partnership (Limited Partnership) are parties acting in concert with each other, and there is a concerted action relationship.
Description of the company’s top 10 ordinary shareholders and shareholders without selling restrictions participating in margin trading and securities lending business:
- Shareholder Shi Shilin holds 0 shares of the company through an ordinary securities account, and holds 0 shares of the company through a customer credit transaction guaranteed securities account of China Merchants Securities Co., Ltd.
1,530,000 shares, a total of 1,530,000 shares held.
- Shareholder Shanghai Ah Xing Investment Management Co., Ltd. - Ah Xing Xing No. 2 Private Securities Investment Fund holds 0 shares of the company through ordinary securities accounts, and holds 1,400,400 shares of the company through the customer credit transaction guaranteed securities account of Huatai Securities Co., Ltd., a total of the top 10 shareholders participating in the margin trading and securities lending business. Description of the shareholders (such as
Holds 1,400,400 shares.
Yes)
The shareholder Zhejiang Yinwan Private Fund Management Co., Ltd. - Yinwan Quanying No. 66 Private Securities Investment Fund holds 0 shares of the company through ordinary securities accounts and 1,362,300 shares of the company through the customer credit transaction guaranteed securities account of Cathay Haitong Securities Co., Ltd., holding a total of 1,362,300 shares.
The shareholder Zhejiang Yinwan Private Fund Management Co., Ltd. - Yinwan Quanying No. 16 Private Securities Investment Fund holds 0 shares of the company through ordinary securities accounts and 757,400 shares of the company through the customer credit transaction guaranteed securities account of Cathay Haitong Securities Co., Ltd., for a total of 757,400 shares.
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable Not applicable
(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders
□Applicable Not applicable
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
(3) Changes in restricted shares
Applicable □Not applicable
Unit: Share
Restrictions on sales are lifted in this period. Restrictions on sales are added in this period. Name of shareholder on the date when restrictions on sales are to be lifted. Number of shares subject to restrictions on sales at the beginning of the period. Number of shares subject to restrictions on sales at the end of the period. Reasons for restrictions on sales.
Number of shares Number of shares Period
The shares issued before the initial public offering held by Mr. Zhang Jun, the company's shareholder, will be available for listing on the 24th of February 2025. Zhang Jun 19,627,034 19,627,034 14,720,275 14,720,275 Executive locked shares; the shares of current directors, supervisors and senior executives will be locked every year according to 75% of the total number held at the end of the previous year.
The shares of the current directors, supervisors and senior management are locked every year at 75% of the total number of shares held by them at the end of the previous year; senior executives of the company Shi Yingxiu 1,479,088 0 15,000 1,494,088 Senior management increased their holdings of the company's shares through the secondary market during the reporting period, and the newly unrestricted shares are automatically locked at 75% of the shares of the current directors, supervisors and senior management according to their holdings. Meng Yonghong 1,032,187 0 0 1,032,187 executive locked shares, 75% of the total held at the end of the previous year were locked
The shares of current directors, supervisors and senior executives are locked every year according to 75% of the total number of shares held by them at the end of the previous year; all the company shares held by the outgoing supervisors will be locked within six months of leaving office. The outgoing supervisors will be locked
Hou Yulin 700,000 62,500 212,500 850,000 Fixed, upon his inauguration
During the term determined at the time and within six months after the expiration of the term, the shares transferred each year shall not exceed 25% of the total number of shares of the company held by it.
Total 22,838,309 19,689,534 14,947,775 18,096,550 -- --
3. Other important matters
Applicable □Not applicable
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
- During the reporting period, the levofloxacin eye drops applied by the company received the "Drug Registration Certificate" issued by the State Food and Drug Administration. For details, please refer to the company's
"Announcement on the Company's Levofloxacin Eye Drops Obtaining a Drug Registration Certificate" disclosed on the cninfo.com (www.cninfo.com.cn) on July 4, 2025.
4. Quarterly Financial Statements
(1) Financial statements
- Consolidated balance sheet
Prepared by: Jilin Xidian Pharmaceutical Technology Development Co., Ltd.
September 30, 2025
Unit: Yuan
Item Ending balance Beginning balance
Current assets:
Monetary funds 85,281,923.34 190,678,612.90 Settlement reserves
Loan funds
Trading financial assets 158,559,451.55 84,926,079.34 Derivative financial assets
Notes receivable 25,381,354.15 20,694,586.18 Accounts receivable 39,732,549.05 36,733,402.52 Accounts receivable financing
Prepayments 14,724,677.20 5,600,619.99 Premiums receivable
Reinsurance accounts receivable
Receivable reinsurance contract reserves
Other receivables 3,504,166.64 3,964,118.42 Including: interest receivable
Dividends receivable
Buy financial assets under resale agreements
Inventory 25,970,135.78 27,972,598.48
Among them: data resources
contract assets
Assets held for sale
Non-current assets due within one year
Other current assets 2,175,681.83 2,339,681.78 Total current assets 355,329,939.54 372,909,699.61 Non-current assets:
Grant loans and advances
debt investment
Other debt investments
long-term receivables
Long-term equity investment 1,000,000.00
Other equity instrument investments
Other non-current financial assets
investment real estate
Fixed assets 442,430,060.82 314,780,305.26 Construction in progress 69,242,184.99 192,827,353.86 Productive biological assets
oil and gas assets
Right-of-use assets 96,446.22 183,247.80 Intangible assets 94,078,960.96 99,849,499.33
Among them: data resources
development expenditure
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
Among them: data resources
Goodwill 30,568,803.03 30,568,803.03 Long-term deferred expenses
Deferred income tax assets 8,969,749.02 7,918,230.73 Other non-current assets 51,441,656.02 43,538,364.17 Total non-current assets 697,827,861.06 689,665,804.18 Total assets 1,053,157,800.60 1,062,575,503.79 Current liabilities:
Short-term borrowing 10,000,000.00 borrowed from the central bank
borrowing funds
Trading financial liabilities
Derivative financial liabilities
Notes payable
Accounts payable 29,934,304.59 42,430,903.53 Advance payments
Contract liabilities 1,559,281.15 2,418,737.33 Financial assets sold and repurchased
Taking deposits and placing deposits with other banks
Agent for buying and selling securities
Agent underwriting securities funds
Employee benefits payable 2,234,187.97 2,070,149.85 Taxes payable 4,450,475.51 3,203,639.26 Other payables 17,913,291.91 18,474,627.93 Including: interest payable
Dividends payable
Handling fees and commissions payable
Reinsurance accounts payable
Liabilities held for sale
Non-current liabilities due within one year 102,930.72 192,851.96 Other current liabilities 201,158.94 314,435.86 Total current liabilities 56,395,630.79 79,105,345.72 Non-current liabilities:
insurance contract reserves
Long-term borrowings 10,000,000.00
bonds payable
Among them: preferred shares
perpetual bond
Lease liabilities 76,070.24 Long-term payables
Long-term employee benefits payable
Estimated liabilities
Deferred income 34,481,469.03 37,124,128.59 Deferred income tax liabilities 4,858,534.37 5,106,032.28 Other non-current liabilities
Total non-current liabilities 49,340,003.40 42,306,231.11 Total liabilities 105,735,634.19 121,411,576.83 Owners’ equity:
Share capital 76,494,685.00 80,803,943.00 Other equity instruments
Among them: preferred shares
perpetual bond
Capital reserve 363,600,105.51 461,371,836.82 Less: treasury shares 100,013,941.06 Other comprehensive income
Special reserves 2,438,185.38 2,643,596.51
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
Surplus reserve 69,225,276.44 69,225,276.44 General risk reserve
Undistributed profits 404,973,506.94 391,715,762.62 Total owners’ equity attributable to the parent company 916,731,759.27 905,746,474.33 Minority shareholders’ equity 30,690,407.14 35,417,452.63 Total owners’ equity 947,422,166.41 941,163,926.96 Total liabilities and owners’ equity 1,053,157,800.60 1,062,575,503.79 Legal representative: Zhang Jun Person in charge of accounting work: Meng Si Person in charge of accounting department: Wei Xiangru
- Consolidated income statement from the beginning of the year to the end of the reporting period
Unit: Yuan
Item Amount for the current period Amount for the previous period
- Total operating income 188,945,385.60 192,581,520.03 Including: operating income 188,945,385.60 192,581,520.03 Interest income
Premiums earned
Fee and commission income
- Total operating costs 159,135,919.32 160,706,213.91 Including: operating costs 41,512,253.73 42,667,316.81 Interest expenses
Handling fees and commission expenses
surrender deposit
Net compensation expenses
Net withdrawal of insurance liability reserves
policy dividend payout
Reinsurance cost
Taxes and surcharges 5,476,290.70 4,394,436.84 Sales expenses 74,798,184.74 84,092,570.97 Management expenses 29,393,766.93 21,723,083.66 Research and development expenses 7,978,718.67 10,025,178.80Financial expenses -23,295.45 -2,196,373.17Including: Interest expenses 362,725.03 57,272.94
Interest income 407,071.91 2,281,544.09 plus: other income 3,667,779.69 5,205,516.81 investment income (losses are filled in with "-"
2,552,898.35 2,767,345.52 columns)
Of which: for associates and joint ventures
corporate investment income
Measured at amortized cost
Income from derecognition of financial assets
Exchange gains (losses are filled in with "-"
column)
Net exposure hedging gain (loss calculated as
Fill in the column with "-" sign)
Gains from changes in fair value (losses calculated as
551,037.55 1,120,360.42 (Fill in “-”)
Credit impairment losses (losses are marked with "-"
-407,365.70 -823,450.53 fill in the column)
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
Asset impairment losses (losses are marked with "-"
-71,366.75 -471,032.23 fill in the column)
Asset disposal income (losses are listed with "-")
3. Operating profit (loss is filled in with "-"
36,102,449.42 39,674,046.11 columns)
Add: Non-operating income 68,000.81 54.59Minus: Non-operating expenses 6,006.83 704,671.57
- Total profits (total losses are marked with “-”
36,164,443.40 38,969,429.13 fill in the column)
Less: Income tax expenses 4,812,174.71 4,902,896.89
5. Net profit (net loss is filled in with "-"
31,352,268.69 34,066,532.24 columns)
(1) Classification by business continuity
- Net profit from continuing operations (net loss divided by
31,352,268.69 34,066,532.24 (Fill in “-”)
- Net profit from discontinued operations (net loss equal to
Fill in the column with "-" sign)
(2) Classification according to ownership ownership
- Net profit attributable to shareholders of the parent company
33,146,362.42 34,066,532.24 (Net loss is listed with "-")
- Profit and loss of minority shareholders (net loss is represented by “-”
-No. 1,794,093.73 (please fill in the list)
6. Net amount of other comprehensive income after tax
Other comprehensive income, net of tax, attributable to owners of the parent company
(1) Other comprehensive income that cannot be reclassified into profit or loss
Remeasure the changes in defined benefit plan
Other comprehensive income that cannot be transferred to profit or loss under the equity method
Changes in fair value of other equity instrument investments
Changes in the fair value of the company’s own credit risk
5.Others
(2) Other comprehensive income that will be reclassified into profit and loss
Other comprehensive income that can be converted to profit or loss under the equity method
Changes in fair value of other debt investments 3. Amount of financial assets reclassified and included in other comprehensive income
Credit impairment provisions for other debt investments 5. Cash flow hedging reserves
Translation differences of foreign currency financial statements
7.Others
Other comprehensive income, net of tax, attributable to minority shareholders
- Total comprehensive income 31,352,268.69 34,066,532.24
(1) Comprehensive assets attributable to owners of the parent company
33,146,362.42 34,066,532.24Total income
(2) Comprehensive income attributable to minority shareholders
-1,794,093.73 total
8. Earnings per share:
(1) Basic earnings per share 0.4333 0.4351
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
(2) Diluted earnings per share 0.4333 0.4351 If a business merger under common control occurs in this period, the net profit realized by the merged party before the merger is: 0.00 yuan, and the net profit realized by the merged party in the previous period is: 0.00 yuan.
Legal representative: Zhang Jun Person in charge of accounting work: Meng Si Person in charge of accounting department: Wei Xiangru
- Consolidated cash flow statement from the beginning of the year to the end of the reporting period
Unit: Yuan
Item Amount for the current period Amount for the previous period
1. Cash flow generated from operating activities:
Cash received from sales of goods and provision of services 204,287,879.04 204,494,836.84 Net increase in customer deposits and interbank deposits
Net increase in borrowing from the central bank
Net increase in borrowing funds from other financial institutions
Cash received from premiums from the original insurance contract
Net cash received from reinsurance business
Net increase in policyholders’ savings and investment funds
Cash collected from interest, fees and commissions
Net increase in borrowing funds
Net increase in repurchase business funds
Net cash received from buying and selling securities on behalf of agents
tax refund received
Other cash received related to operating activities 4,134,166.05 7,554,757.55 Subtotal of cash inflows from operating activities 208,422,045.09 212,049,594.39 Cash paid for purchasing goods and receiving services 32,372,383.64 26,564,946.28 Net increase in customer loans and advances
Net increase in deposits with central banks and inter-banks
Cash used to pay compensation from the original insurance contract
Net increase in lending funds
Cash payments for interest, fees and commissions
Cash payment for policy dividends
Cash paid to and for employees 24,169,868.74 20,143,009.36 Various taxes paid 26,061,967.23 23,983,794.29 Cash paid for other operating activities 87,307,801.26 95,274,847.82 Subtotal of cash outflows from operating activities 169,912,020.87 165,966,597.75 Net cash flow generated from operating activities 38,510,024.22 46,082,996.64
2. Cash flow generated from investing activities:
Cash received from recovery of investment 779,669,042.14 765,427,454.08 Cash received from investment income 3,300,517.03 5,914,327.57 Disposal of fixed assets, intangible assets and other long-term assets
Net cash received from period assets
Received from disposal of subsidiaries and other business units
net cash
Other cash received related to investing activities
Subtotal of cash inflows from investing activities 782,969,559.17 771,341,781.65 Purchase and construction of fixed assets, intangible assets and other long-term assets
46,937,701.01 119,452,508.34 Cash paid for assets
Cash paid for investment 854,500,000.00 760,471,576.85 Net increase in pledged loans
Obtain payment from subsidiaries and other business units
net cash
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. 2025 Third Quarter Report
Other cash payments related to investing activities
Subtotal of cash outflows from investing activities 901,437,701.01 879,924,085.19 Net cash flow generated from investing activities -118,468,141.84 -108,582,303.54
3. Cash flow generated from financing activities:
Absorbing cash received from investments
Among them: subsidiaries absorb investment from minority shareholders
cash received
Cash received from borrowing 10,000,000.00
Other cash received related to financing activities
Subtotal of cash inflows from financing activities 10,000,000.00
Cash paid to repay debts 10,000,000.00
Distribution of dividends, profits or repayment of interest payments
20,234,062.58 20,015,394.10 cash
Including: Payments made by subsidiaries to minority shareholders
dividends, profits
Cash payments related to other financing activities 5,204,847.72 98,659,742.78 Subtotal cash outflows from financing activities 35,438,910.30 118,675,136.88 Net cash flow generated from financing activities -25,438,910.30 -118,675,136.88
4. The impact of exchange rate changes on cash and cash equivalents
influence
- Net increase in cash and cash equivalents -105,397,027.92 -181,174,443.78
Add: Balance of cash and cash equivalents at the beginning of the period 190,117,393.92 333,810,194.10
- Balance of cash and cash equivalents at the end of the period 84,720,366.00 152,635,750.32
(2) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2025
□Applicable Not applicable
(3) Audit report
Whether the third quarter financial accounting report has been audited
□Yes No
The company's third quarter financial accounting report has not been audited.
Board of Directors of Jilin Xidian Pharmaceutical Technology Development Co., Ltd.
October 28, 2025